December 07, 2021
Read for 1 minute
Source / information
Published by:
Disclosure:
Belay reports that he has received grants for Pfizer COVID-9 vaccine studies. Please refer to the study for all relevant financial information from the other authors.
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If this problem persists, please contact [email protected].
Back to Healio
According to a study published in Clinical Infectious Diseases, researchers found no pattern of multisystem inflammatory syndrome in adults after receiving a COVID-19 vaccination without prior SARS-CoV-2 infection.
SARS-CoV-2 infection can cause multisystem inflammatory syndrome (MIS-A) in adults and a similarly severe illness in children, MIS-C, days or weeks after the illness, causing symptoms in different parts of the body.
There was no general pattern of multisystem inflammatory syndrome in adults following COVID-19 vaccination without prior SARS-CoV-2 infection. Source: Adobe Stock.
Ermias D. Belay
In the new study Ermias D. Belay MD, a member of the CDC’s COVID-19 Response Team, and colleagues stated that “MIS-A has been added to the list of adverse events to be monitored as part of the emergency permits issued for COVID-19 vaccines.”
“The study was initiated to follow up cases of people suspected of having multisystem inflammatory syndrome in adults after the COVID-19 vaccine became available to learn more about and test for MIS-A and determine if the COVID -19 vaccination affects MIS-A. ”A CDC spokesman told Healio.
For the study, Belay and colleagues evaluated reports from patients with MIS-A that the CDC received after COVID-19 vaccines became available between December 14, 2020 and April 30, 2021.
The assessment revealed 20 patients who met the case definition for MIS-A, including 16 (80%) who had a median previous COVID-19-like illness averaging 26 days prior to the start of MIS-A. All 20 patients had laboratory evidence of SARS-CoV-2 infection.
Of the 20 patients, seven (35%) had received a median COVID-19 vaccine 10 days before the onset of MIS-A, and three had a second dose of COVID-19 vaccine 4, 17 and 22 days before MIS-A receive. A beginning.
“Although seven patients were reported to have received a COVID-19 vaccine, all had evidence of previous SARS-CoV-2 infection,” wrote Belay and colleagues. “Given the widespread use of COVID-19 vaccines, the lack of a MIS-A report associated with vaccination alone with no evidence of an underlying SARS-CoV-2 infection is reassuring.”
The CDC spokesman told Healio that “clinics and health department officials should be familiar with the MIS-A case definition and ensure that suspected cases are reported,” as the disease is severe and difficult to detect.
ADD SUBJECT TO EMAIL ALERTS
Receive an email when new articles are published on
Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If this problem persists, please contact [email protected].
Back to Healio
